The upstream kinase of Paxillin, FAK, is also shown to be highly expressed and activated in many types of cancers (Miyazaki et al., 2003; Itoh et al., 2004; Cance et al., 2000; Madan et al., 2006), and has been used as a therapeutic target for cancer treatment, including pancreatic cancer and non-small-cell lung carcinoma (Gerber et al., 2020; Parsons et al., 2008). Here, PTK2 is linked to non-small cell lung carcinoma.